TNP-470 promotes initial vascular sprouting in xenograft tumors

Molecular Cancer Therapeutics

Volumn 3, Issue 3, 2004, Pages 335-343

  Huang, Jianzhong ^a   Frischer, Jason S ^a   New, Tamara ^a   Kim, Eugene S ^a   Serur, Anna ^a   Lee, Alice ^a   Kadenhe Chiwishe, Angela ^a   Pollyea, Daniel A ^a   Yokoi, Akiko ^a   Holash, Jocelyn ^b   Yancopoulos, George D ^b   Kandel, Jessica J ^a   Yamashiro, Darell J ^a  

^a Surgeons of Columbia University ^*  (United States)

^b REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; PIMONIDAZOLE; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASSAY; CANCER INHIBITION; CAPILLARY DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SELECTIVITY; ENDOTHELIUM; FEMALE; GENE EXPRESSION; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; MOUSE; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANGIOGRAPHY; ANIMALS; ANOXIA; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CAPILLARIES; CELL LINE, TUMOR; CYCLOHEXANES; FLUORESCEIN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN SITU NICK-END LABELING; LECTINS; MICE; MICE, NUDE; MICROCIRCULATION; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITROIMIDAZOLES; RADIATION-SENSITIZING AGENTS; SESQUITERPENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WILMS TUMOR;

EID: 4444296218     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer. Exp Opin Biol Ther, 2003;3:263-76.
2. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth, Nature, 1990; 348:555-7.
3. Kusaka M, Sudo K, Fujita T, et al. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun, 1991;174:1070-6.
4. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res, 1993;53:5233-6.
5. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470). Cancer Res, 1993;53:4262-7.
6. Kurebayashi J, Kurosumi M, Dickson RB, Sonoo H. Angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) inhibits tumor angiogenesis, growth and spontaneous metastasis of MKL-4 human breast cancer cells in female athymic nude mice. Breast Cancer, 1994;1:109-15.
7. Griffith EC, Su Z, Turk BE, et al. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol, 1997;4:461-71.
8. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA, 1997;94: 6099-103.
9. Bradshaw RA, Yi E. Methionine aminopeptidases and angiogenesis. Essays Biochem, 2002;38:65-78.
10. Bernsen HJ, Rijken PF, Peters H, Bakker H, van der Kogel AJ. The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J Neurooncol, 1998;38:51-7.
11. Katzenstein HM, Rademaker AW, Sanger C, et al. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res, 1999;5:4273-8.
12. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res, 2001;7:977-84.
13. Morales C, Zurita M, Vaquero J. Antitumor effect of TNP-470 is not associated to decrease of angiogenesis in an experimental malignant neuroectodermic tumor. J Neurooncol, 2002;58:131-6.
14. Emoto M, Ishiguro M, Iwasaki H, Kikuchi M, Kawarabayashi T. Effect of angiogenesis inhibitor TNP-470 on the growth, blood flow, and microvessel density in xenografts of human uterine carcinosarcoma in nude mice. Gynecol Oncol, 2003;89:88-94.
15. Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol, 1999;17:2541-5.
16. Logothetis CJ, Wu KK, Finn LD, et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res, 2001;7:1198-203.
17. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA, 2002;99: 11393-8.
18. Wild R, Ramakrishnan S, Sedgewick J, Griffioen AW. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res, 2000;59:368-76.
19. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science, 1999;284:1994-8.
20. Rowe DH, Huang J, Kayton ML, et al. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg, 2000;35:30-2; discussion 32-33.
21. Rowe DH, Huang J, Li J, et al. Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg, 2000;35: 977-81.
22. Huang J, Moore J, Soffer S, et al. Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J Pediatr Surg, 2001;36:357-61.
23. Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA, 2002;99:11399-404.
24. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 1992;359:843-5.
25. Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA, 2003;100:7785-90.
26. Koyama H, Nishizawa Y, Hosoi M, et al. The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-I. Possible involvement of cyclin-dependent kinase 2. Circ Res, 1996;79: 757-64.
27. Emoto M, Ishiguro M, Iwasaki H, Kikuchi M, Kawarabayashi T. TNP-470 inhibits growth and the production of vascular endothelial growth factor of uterine carcinosarcoma cells in vitro. Anticancer Res, 2000; 20:601-4.
28. Rodriguez-Nieto S, Medina MA, Quesada AR. A re-evaluation of fumagillin selectivity towards endothelial cells. Anticancer Res, 2001; 21:3457-60.
29. Yeh JR, Mohan R, Crews CM. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci USA, 2000;97:12782-7.
30. Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci USA, 2000;97:6427-32.
31. Wang J, Lou P, Henkin J. Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem, 2000;77:465-73.